BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
2450407
Number of visits today
510
Number of downloads
1634221
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Ridruejo E, Mendizabal M, Silva MO. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease: HCV in CKD stages 2-3. Hemodialysis International 2018;22:S97-S103. [DOI: 10.1111/hdi.12651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
2 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
3 Elmowafy AY, El Maghrabi HM, Mashaly ME, Eldahshan KF, Rostaing L, Bakr MA. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. Int Urol Nephrol 2019;51:2243-54. [PMID: 31612423 DOI: 10.1007/s11255-019-02316-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Ridruejo E, Garcia-Agudo R, Mendizabal M, Aoufi-Rabih S, Dixit V, Silva M, Fabrizi F. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrologia (Engl Ed) 2020;40:46-52. [PMID: 31229261 DOI: 10.1016/j.nefro.2019.03.013] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345